Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
|
|
- Baldwin Shaw
- 6 years ago
- Views:
Transcription
1 AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi: /aac Copyright 2016, American Society for Microbiology. All Rights Reserved Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Pranita D. Tamma, MD, MHS 1#, Yanjie Huang, ScM, BM 2,, Belita N.A. Opene, MS 3, & Patricia J. Simner, PhD Division of Pediatric Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 3 Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA #Corresponding Author Pranita D. Tamma, M.D., M.H.S. The Johns Hopkins University School of Medicine 200 North Wolfe St., Suite 3149 Baltimore, MD Tel (443) ptamma1@jhmi.edu Key words: CRE; KPCs; NDM; ROC curve; β-lactamases Abbreviated Title: Differentiating carbapenemase-producing and non-carbapenemase producing CRE Word count of body of text:
2 Abstract Carbapenemase-producing (CP) Enterobacteriaceae are largely responsible for the rapid spread of carbapenem-resistant Enterobacteriaceae (CRE). Distinguishing CP-CRE and non- CP-CRE has important infection control implications. In a cohort of 198 CRE isolates, an ertapenem MIC of 0.5 µg/ml and meropenem, imipenem, or doripenem MICs of 2 µg/ml were best able to distinguish CP and non-cp CRE isolates
3 Carbapenem-resistant Enterobacteriaceae (CRE) encompass both carbapenemase-producers (CP) and non-carbapenemase-producers (non-cp). CP-CRE are particularly concerning from an infection control standpoint as the genes encoding carbapenemases are generally located on mobile genetic elements (i.e., plasmids, transposons, insertion sequences) and are easily transmissible to other gram-negative organisms [1]. In the United States, carbapenemase genes are most commonly bla KPCs [2]. However, in large part due to international migration and medical tourism, other carbapenemase genes (e.g., bla NDMs, bla VIMs, bla IMPs, and bla OXAs) have also been increasingly encountered [3]. Gram-negative organisms harboring these resistance genes can spread easily from patient to patient in healthcare settings. In fact, CP-CRE have been responsible for a number of outbreaks in the healthcare environment [1]. On the contrary, non-cp-cre generally emerge as the result of heterogeneous mechanisms, such as reduced outer membrane permeability, and have been associated with a loss of organism fitness and reduced transmissibility [1]. Distinguishing these resistance mechanisms has important infection control implications The Centers for Disease Control and Prevention (CDC) acknowledges that CP-CRE are currently believed to be primarily responsible for the increasing spread of CRE in the United States and have therefore been targeted for aggressive prevention and that a reliable way to differentiate CP-CRE from non-cp-cre might help guide such targeting by identifying the organisms of greatest epidemiological interest [4]. Determining whether a CRE is carbapenemase-producing involves several additional steps in the microbiology laboratory and can be resource intensive. As a result, many US clinical microbiology laboratories are not conducting additional phenotypic tests such as the Carba NP test or modified Hodge test to determine if CRE are indeed CP-CRE [2]. These tests have limitations in their ability to detect some CP genes (e.g., Carba NP are limited in detection of bla OXA-48-types and the modified Hodge test is limited in detecting metallo-β-lactamases) [5, 6].
4 Currently, most healthcare facilities institute contact precautions when patients with CRE are identified and subsequently perform unit-wide point prevalence studies to identify other unrecognized carriers on the unit when CRE clinical isolates are identified, according to CDC recommendations [7]. We sought to determine whether an optimal carbapenem MIC can reliably distinguish CP-CRE and non-cp-cre, potentially lessening the burden on microbiology laboratories We included well-characterized CRE isolates from the Antimicrobial Resistance Isolate Bank between 2012 and 2015 [8] (n=145) and all CRE bloodstream isolates from unique patients at The Johns Hopkins Hospital between 2014 and 2015 (n=53) (Table 1). The Antimicrobial Resistance Isolate Bank is a repository of bacteria with genotypic and susceptibility data that have been assembled by the CDC and Food and Drug Administration. For The Johns Hopkins Hospital isolates, ertapenem, meropenem, imipenem, and doripenem MICs were determined using the Etest (biomérieux). Carbapenem resistance was defined according to the Clinical Laboratory and Standards Institute criteria (CLSI) with ertapenem resistance defined as 2mcg/ml and meropenem, imipenem, and doripenem resistance defined as MICs 4 mcg/ml [9]. β-lactamase gene identification was performed using the Check-MDR CT103XL assay (Check-Points, Wageningen, The Netherlands). The Check-MDR CT103XL assay combines PCR amplification and micro-array technologies for the detection of an extended panel of carbapenemase genes (bla KPC, bla NDM, bla VIM, bla IMP, bla OXA-48-like, bla GES, bla GIM, bla SPM, bla OXA-23- like, bla OXA-24/40-like, bla OXA-58-like ). [10] We created histograms to distinguish the MIC range of CP and non-cp-cre individually for ertapenem, meropenem, imipenem, and doripenem. The Wilcoxan rank-sum test was used to compare medians and interquartile ranges (IQR) between carbapenem MICs for CP-CRE and
5 non-cp-cre for each of the antibiotics, with a two-tailed P value of <0.05 considered statistically significant. A receiver operating characteristic (ROC) curve was generated to determine the optimal MIC for the detection of CP-CRE using various carbapenem MICs. The discriminatory power was evaluated using the area under the ROC curve (AUC), with an AUC value of 0.5 indicating no discriminative ability and an AUC exceeding 0.8 indicating good to excellent prediction. The sensitivity and specificity of the prediction rule were calculated at various carbapenem MIC values. Statistical analyses were performed using the R statistical package There were 135 (68%) CP-CRE and 63 (32%) non-cp-cre isolates. The genus and species of the full cohort are displayed in Table 1. For the 53 Johns Hopkins Hospital isolates, the most commonly recovered organisms were Klebsiella pneumoniae (53%), Enterobacter spp. (42%), and E. coli (5%). Evaluating the full cohort, the CP-CRE isolates contained a variety of serine and metallo-β-lactamase carbapenemase genes; encoding Class A carbapenemases [bla KPC (n=58), bla SME (n=7), bla IMI (n=2)]; Class B carbapenemases [bla NDM (n=38), bla IMP (n=4), bla VIM (n=9)]; and Class D carbapenemases [bla OXA-48-type (n=17)], Table 1. Twenty-three (43%) of the Johns Hopkins Hospital isolates were CP-CRE, including 21 (92%) bla KPCs, 1 (4%) bla NDM, and 1 (4%) bla OXA-48-type The distribution of MICs for each of the carbapenems is displayed in Figure 1. The median and IQR for the carbapenems tested against CP-CRE were as follows: ertapenem [16 µg/ml, 8-16 µg/ml], meropenem [16 µg/ml, 4-16 µg/ml], imipenem [16 µg/ml, 4-64 µg/ml], doripenem [16 µg/ml, 4-16 µg/ml]. The median and IQR amongst non-cp CRE were as follows: ertapenem [2 µg/ml, µg/ml], meropenem [1 µg/ml, 1-2 µg/ml], imipenem [1 µg/ml, 1-2 µg/ml], doripenem [1 µg/ml, µg/ml]. For each of these antibiotics, the distributions of carbapenem MICs for CP and non-cp-cre were significantly different (P <0.01). Comparing isolates
6 producing the most frequent carbapenemase genes identified in the United States, bla KPC, bla NDM, and bla OXA-48-like, no differences in the carbapenem MIC distributions were noted; however, there were small numbers of carbapenemases other than bla KPCs and bla NDMs in our cohort, limiting a robust comparison of the MIC distributions for the different carbapenemases We developed an ROC curve for each of the carbapenem antibiotics to identify the carbapenem MIC that best distinguishes CP and non-cp-cre (Figure 2). For ertapenem, a group 1 carbapenem, the AUC of the ROC curve was An MIC cutoff of 0.5 µg/ml had the greatest overall sensitivity and specificity for distinguishing CP-CRE from non-cp CRE, which were 98.2% and 61.1%, respectively. In contrast, the AUC was over 0.90 for meropenem, imipenem, and doripenem, group 2 carbapenems, with sensitivities ranging from 89.5% to 94.5% and specificities ranging from 77.8% to 83.3% - indicating these agents had excellent discriminatory ability to distinguish CP and non-cp-cre at an MIC of 2 µg/ml. Of note, as has been previously described in the literature (11), the 3 included Proteus mirabilis isolates had imipenem MICs well above 2 µg/ml (i.e., µg/ml) and significantly higher than the respective meropenem MICs (0.5-4 µg/ml) The use of an MIC cutoff to distinguish CP-CRE and non-cp-cre, if a useful cutoff exists, could reduce the burden of clinical microbiology laboratories when deciding to conduct point prevalence surveillance studies if a patient with a CRE is identified. Additionally, a reliable MIC cutoff could avoid the additional steps involved in implementing phenotypic methods to distinguish CP and non-cp-cre. Our data suggest that based on a carbapenem ROC curve, group 2 carbapenem MICs of 2 µg/ml represent the carbapenem antibiotics and MIC cutoff that are best able to discriminate between CP and non-cp CRE. However, using group 2 carbapenem MICs to distinguish CP-CRE and non-cp-cre would translate to about 5-10% of CP-CRE remaining undetected. Although an ertapenem MIC of 0.5 µg/ml is highly sensitive for
7 7 157 detecting CP-CRE, it is associated with a specificity of only approximately 60% There are pros and cons to using ertapenem versus group 2 carbapenems to make the distinction between CP-CRE and non-cp-cre. Using nonsusceptibility of ertapenem to distinguish CP and non-cp-cre could result in a large portion of non-cp-cre erroneously designated as CP-CRE, however, it would ensure that almost all patients with a CP-CRE could be rapidly identified and placed on contact precautions, potentially limiting their spread in healthcare institutions. Because of the significant morbidity and mortality associated with CP- CRE infections, we favor approaches to optimize the sensitivity of CP-CRE detection, even if it means some compromise in the specificity There are limitations with our study. We realize that susceptibility patterns may change over time and that these data need to be periodically reviewed to remain accurate. Additionally, we realize that the assortment of carbapenemases and proportion of CP-CRE and non-cp-cre may not be generalizable to what is found in clinical practice and that these data will vary based on local epidemiology. In our cohort, the majority of carbapenemases were bla KPCs, followed by bla NDMs. While this is consistent with what others have observed in the United States, it differs from carbapenemase distributions observed globally and it is not known if our findings would be replicated in settings outside of the United States Nonetheless, until rapid, accurate, cost-effective, and standardized methods of carbapenemase detection are available in clinical microbiology laboratories across the country, we believe that other approaches might be useful to differentiate CP and non-cp-cre. We encourage other research groups to repeat these analyses with a larger cohort to increase the accuracy of carbapenem MICs to distinguish CP and non-cp-cre. 182
8 Acknowledgements P.D.T. received support from the inhealth Pilot Project Discovery Program and P.J.S. received support from the Fisher Center Discovery Program award supported by Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases. All authors report no conflicts of interest relevant to this article
9 References 1. Goodman KE, Simner PJ, Tamma PD, & Milstone AM. Infection control implications of heterogeneous resistant mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Expert Rev Infect Ther 2016;1: Chea N, Bulens SN, Knogphet-Tran T, et al. Improved phenotype-based definition for identifying carbapenemase-producers among carbapenem-resistant Enterobacteriaceae. Emerg Infect Dis 2015;21(9): Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 10: Centers for Disease Control and Prevention. FAQs about choosing and implementing a CRE definition. Accessed June 27 th, Tijet N, Boyd D, Patel SN, Mulvey MR, and Melano RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2103; 57(9): Girlich D, Poirel L, and Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol 2012; 50(2): Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) November 2015 Update CRE Toolkit. Accessed June 27 th, FDA-CDC Antimicrobial Resistance Isolate Bank. Accessed June 27 th, CLSI. Performance standards for antimicrobial susceptibility testing. 26th edition. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; Suwantarat N, Logan LK, Carroll KC, et al. The prevalence and molecular epidemiology of multidrug-resistant Enterobacteriaceae colonization in a pediatric intensive care unit. Infect Cont Hosp Epidemiol 2016 doi: /ice
10 Villar HE, Danel F, Livermore DM: Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams. J Antimicrob Chemother. 1997, 40: /jac/ Figure Legend Figure 1. Distributions of carbapenem-resistant Enterobacteriaceae carbapenem MICs comparing carbapenemase producers and non-carbapenemase producers; (A) Ertapenem, (B) Meropenem, (C) Imipenem, (D) Doripenem; Gray represents non-carbapenemase producers and black represents carbapenemase producers Figure 2. Receiver operating characteristic curve using carbapenem minimum inhibitory concentrations for the detection of carbapenemase-producing carbapenem-resistant Enterobacteriaceae; (A) Ertapenem, (B) Meropenem, (C) Imipenem, and (D) Doripenem
11 Type of β-lactamases Citrobacter amalonaticus (n=1) Citrobacter freundii (n=2) Enterobacter aerogenes (n=7) Enterobacter asburiae (n=1) Enterobacter cloacae (n=40) Escherichia coli (n=30) Klebsiella oxytoca (n=4) Klebsiella ozanae (n=2) Klebsiella pneumoniae (n=96) Morganella morgganii (n=2) Proteus mirabilis (n=3) Providencia rettgeri (n=1) Raoultella spp. (n=1) Salmonella spp. (n=1) Serratia marcescens (n=7) Class A TEM (n=8) ESBL TEM, ACT/MIR (n=3) ESBL + AmpC 3 SHV (n=4) ESBL 2 2 SHV, ACT/MIR (n=3) ESBL + AmpC 3 TEM, CTX-M, SHV (n=6) ESBL 6 CTX-M, SHV (n=4) ESBL 4 CTX-M (n=5) ESBL 1 4 CTX-M, DHA (n=3) ESBL + AmpC 3 TEM, SHV (n=4) ESBL 4 TEM, CTX-M, SHV (n=1) ESBL 1 KPC (n=29) Carbapenemase KPC, TEM, CTX-M, SHV (n=6) ESBL + Carbapenemase 6 KPC, CTX-M, SHV (n=3) ESBL + Carbapenemase 3 KPC, SHV, TEM (n=5) ESBL + Carbapenemase 2 3 KPC, ACT/MIR (n=1) AmpC + Carbapenemase 1 KPC, CTX-M, ACT/MIR (n=1) ESBL + AmpC + Carbapenemase 1 KPC, ACT/MIR, TEM (n=1) ESBL + AmpC+ Carbapenemase 1 KPC, TEM (n=4) ESBL + Carbapenemase 2 2 KPC, SHV (n=8) ESBL + Carbapenemase 8 IMI (n=2) Carbapenemase 2 SME (n=7) Carbapenemase 7 Class B NDM (n=28) Carbapenemase
12 NDM, CTX-M (n=4) ESBL + Carbapenemase 4 VIM (n=8) Carbapenemase 2 6 VIM, CMY (n=1) ESBL + AmpC + Carbapenemase 1 IMP (n=4) Carbapenemase 2 2 NDM, TEM, CTX-M, SHV (n=3) ESBL + Carbapenemase 3 NDM, DHA, CTX-M, SHV (n=3) ESBL + AmpC + Carbapenemase 3 Class C campc (n=8) AmpC 2 6 CMY (n=7) AmpC 7 ACT/MIR (n=7) AmpC 4 3 Class D OXA-48 (n=7) Carbapenemase 3 4 OXA-232 (n=2) Carbapenemase 2 OXA-181 (n=7) Carbapenemase 1 6 OXA-48, CTX-M, SHV, TEM (n=1) ESBL + Carbapenemase 1
13
14
Received 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationImpact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test
Published in which should be cited to refer to this work. Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test Carbapenem
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationMultidrug-resistant organisms are a major public health
Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae Nora Chea, Sandra N. Bulens, Thiphasone Kongphet-Tran, Ruth Lynfield, Kristin M.
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationThe Public Health Benefit of CRE Colonization Testing
The Public Health Benefit of CRE Colonization Testing Allison C Brown, PhD MPH Team Lead, AR Capacities and Special Studies Division of Healthcare Quality Promotion CDC Carbapenem Resistance Serious threat
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationORIGINAL ARTICLE. Julie Creighton and Clare Tibbs. Canterbury Health Laboratories, Christchurch
ORIGINAL ARTICLE Evaluation of the MAST indirect carbapenemase test and comparison with a modified carbapenem inactivation method for the detection of carbapenemase enzymes in Gram-negative bacteria Julie
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationNew Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection
New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection Stephen G. Jenkins, PhD, F(AAM), D(ABMM) Professor of Pathology and Laboratory Medicine Professor of Pathology in Medicine
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationDetecting carbapenemases in Enterobacteriaceae
Detecting carbapenemases in Enterobacteriaceae David Livermore Health Protection Agency, Colindale, London 12 August 2003 Mechanisms of carbapenem R in Enterobacteria Impermeability + AmpC or ESBL Metallo
More informationEnterobacteriaceae with acquired carbapenemases, 2016
Enterobacteriaceae with acquired carbapenemases, 2016 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More information(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales
(Plasmid mediated) Carbapenemases Timothy R. Walsh, Cardiff University, Wales What is a carbapenemase? How much carbapenem do they need to breakdown before they are called a carbapenemase? ESBL-enzymes
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationUse of Faropenem as an Indicator of Carbapenemase Activity
JCM Accepts, published online ahead of print on 10 April 2013 J. Clin. Microbiol. doi:10.1128/jcm.00720-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Use of Faropenem as
More informationAbstract. Introduction. Editor: R. Canton
ORIGINAL ARTICLE BACTERIOLOGY A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry,
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationEducational Workshops 2016
Educational Workshops 2016 Keynote CPE Screening We are grateful to Dr Andrew Dodgson, Consultant Microbiologist, Public Health England and Central Manchester Hospitals NHS Foundation Trust Terminology
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationEvaluation of Six Phenotypic Methods for the Detection of Carbapenemases in Gram-Negative Bacteria With Characterized Resistance Mechanisms
Original Article Clinical Microbiology Ann Lab Med 2017;37:305-312 https://doi.org/10.3343/alm.2017.37.4.305 ISSN 2234-3806 eissn 2234-3814 Evaluation of Six Phenotypic Methods for the Detection of Carbapenemases
More informationEpidemiology of the β-lactamase resistome among Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in the Chicago region
Epidemiology of the β-lactamase resistome among Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in the Chicago region Michael Y. Lin MD MPH 1, Karen Lolans BS 1, Rosie D. Lyles,
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationSupplementary Material Hofko M et al., Detection of carbapenemases by real-time PCR and melt-curve analysis on the BD MAX TM System
Supplementary Material Hofko M et al., Detection of carbapenemases by real-time PCR and melt-curve analysis on the BD MAX TM System Supplementary Material and Methods Characterization of isolates by the
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Carbapenemase-producing Enterobacteriaceae (CPE) infection or
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationEnterobacteriaceae with acquired carbapenemases, 2015
Enterobacteriaceae with acquired carbapenemases, 2015 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationA new diagnostic microarray (Check-KPC ESBL) for detection and. identification of extended-spectrum beta-lactamases in highly resistant
JCM Accepts, published online ahead of print on 8 June 2011 J. Clin. Microbiol. doi:10.1128/jcm.02087-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationAbstract. a Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 *
RESEARCH ARTICLE Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 * 1
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationCarbapenemase-producing Enterobacteriaceae
Carbapenemase-producing Enterobacteriaceae 2012 CNR Associé Résistance aux Antibiotiques Prof. P. Nordmann Carbapenemases in Enterobacteriaceae May, 2012 Penicillins Cephalosporins Carbapenems Extended-spectrum
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationCarbapenem resistance has emerged worldwide in clinical isolates of Enterobacteriaceae. crossm
SUSCEPTIBILITY crossm In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae Meredith A. Hackel, a Olga Lomovskaya, b Michael N. Dudley, b James A. Karlowsky,
More informationDetection of NDM-1-producing Klebsiella pneumoniae in Kenya
AAC Accepts, published online ahead of print on 29 November 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.01247-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationDetecting Carbapenemase-Producing Enterobacteriaceae: why isn t there a single best method?
Detecting Carbapenemase-Producing Enterobacteriaceae: why isn t there a single best method? Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown
More informationEvaluation of carbapenemase screening and confirmation tests in. Enterobacteriaceae and development of a practical diagnostic algorithm
JCM Accepts, published online ahead of print on 29 October 2014 J. Clin. Microbiol. doi:10.1128/jcm.01692-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of carbapenemase
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationβ CARBA Test Rapid detection of carbapenemase-producing Enterobacteriaceae strains Contents 1. INTENDED USE
β CARBA Test 25 68260 Rapid detection of carbapenemase-producing Enterobacteriaceae strains 881159 2015/05 Contents 1. INTENDED USE 2. SUMMARY AND EXPLANATION OF THE TEST 3. PRINCIPLE OF THE PROCEDURE
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationNavigating Through Current and Emerging Issues in Outbreaks
Navigating Through Current and Emerging Issues in Outbreaks 7th GCC Conference on Infection Prevention and Control December 1-3, 2013 Kuwait City, Kuwait William R. Jarvis, M.D. Jason and Jarvis Associates,
More informationIn recent years, the emergence of diverse carbapenemases in
Evaluation of Carbapenemase Screening and Confirmation Tests with Enterobacteriaceae and Development of a Practical Diagnostic Algorithm Florian P. Maurer, Claudio Castelberg, Chantal Quiblier, Guido V.
More informationCARBAPENEMASE PRODUCING ENTEROBACTERIACEAE
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE Veroniek Saegeman Veroniek Saegeman UZLeuven Carbapenemase producing Enterobacteriaceae (CPE) Introduction on antibiotic resistance Classification of ß-lactamases
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationRegional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA)
National Center for Emerging and Zoonotic Infectious Diseases Regional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA) Chris Prestel, MD Epidemic Intelligence Service
More informationInternational transfer of NDM-1-producing Klebsiella. pneumoniae from Iraq to France
AAC Accepts, published online ahead of print on 18 January 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01761-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationThe role of an AMR reference laboratory
The role of an AMR reference laboratory Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Primary purpose: regional AMR threats
More informationon July 8, 2018 by guest
JCM Accepts, published online ahead of print on 16 January 2013 J. Clin. Microbiol. doi:10.1128/jcm.03316-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationEvaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms
ORIGINAL ARTICLE Evaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms Julie Creighton and Hui Wang Canterbury Health Laboratories, Christchurch ABSTRACT
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationEmerging Superbugs. Mark D. Gonzalez, PhD D(ABMM) Children s Healthcare of Atlanta September 7,2018. No financial disclosures
Emerging Superbugs Mark D. Gonzalez, PhD D(ABMM) Children s Healthcare of Atlanta September 7,2018 No financial disclosures Dr Preeti Jaggi courtesy of Stan Shulman Dr Preeti Jaggi courtesy of Stan Shulman
More informationRapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures
ORIGINAL ARTICLE BACTERIOLOGY Rapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures L. Dortet 1,L.Brechard 1, L. Poirel 1,2 and P. Nordmann 1,2 1) Service de Bacteriologie-Virologie,
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationGuidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Produc... Producing Enterobacteriaceae in Acute Care Facilities
Page 1 of 6 Weekly March 20, 2009 / 58(10);256-260 Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase- Producing Enterobacteriaceae in Acute Care Facilities Infection with carbapenem-resistant
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationCRO and CPE: Epidemiology and diagnostic tests
CRO and CPE: Epidemiology and diagnostic tests Scottish Microbiology and Virology Network Scientific Meeting 22 nd April 2016 Katie Hopkins PhD Clinical Scientist, Antimicrobial Resistance and Healthcare
More informationEmergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011.
Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011. Sophie Vaux, Anne Carbonne, Jean-Michel Thiolet, Vincent Jarlier, Bruno Coignard, the RAISIN and Expert Laboratories Group
More informationKPC around the world Maria Virginia Villegas, MD, MSC
KPC around the world Maria Virginia Villegas, MD, MSC Scientific Director Bacterial Resistance and Nosocomial Infections Research Area International Center for Medical Research and Training, CIDEIM, Cali,
More informationDetection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry
JCM Accepts, published online ahead of print on 2 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.01002-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12
More informationStandardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland
Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland Version 1.0 7 June 2017 Revision Date June 2018 Scottish Microbiology and Virology Network (SMVN) SMVN Standardisation
More informationThe Emergence of Carbapenem Resistance in Canada and Globally. CNISP Annual Meeting Delta Ottawa January 19, 2012
The Emergence of Carbapenem Resistance in Canada and Globally CNISP Annual Meeting Delta Ottawa January 19, 2012 2 Overview Carbapenem-resistance in Enterobacteriaceae Klebsiella pneumoniae Carbapenemases
More informationNature and Science 2017;15(10)
Evaluation of Substrate Profile Test for Detection of Metallobetalactamses among Imipenem Resistant Clinical Isolates of Gram Negative Bacteria Tarek El-said El-Banna, Fatma Ibrahim Sonboland Eslam Shaaban
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCarbapenemase Producing Enterobacteriaceae: Screening
Carbapenemase Producing Enterobacteriaceae: Screening Dr David Harvey Consultant Microbiology and Infection Prevention and Control Nov 2015 Aims Is CPE a problem? Does screening have the potential to help?
More informationAbstract. Introduction. Methods. Editor: R. Canton
ORIGINAL ARTICLE BACTERIOLOGY High rate of faecal carriage of extended-spectrum b-lactamase and OXA-48 carbapenemase-producing Enterobacteriaceae at a University hospital in Morocco D. Girlich 1, N. Bouihat
More informationOriginal Article Clinical Microbiology
Original Article Clinical Microbiology Ann Lab Med 2015;35:212-219 http://dx.doi.org/10.3343/alm.2015.35.2.212 ISSN 2234-3806 eissn 2234-3814 Combined Use of the Modified Hodge Test and Carbapenemase Inhibition
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationScottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service
Scottish Microbiology and Virology Network Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service Total number of carbapenemase producing organisms isolated
More informationEvaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam
AAC Accepted Manuscript Posted Online 14 March 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.02969-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of the
More informationHigh Stringency Evaluation of the Automated BD Phoenix CPO Detect and. Running Title: Phenotypic Carbapenemase Detection and Classification
JCM Accepted Manuscript Posted Online 4 October 2017 J. Clin. Microbiol. doi:10.1128/jcm.01215-17 Copyright 2017 Thomson et al. This is an open-access article distributed under the terms of the Creative
More informationRapid detection of carbapenemase-producing Pseudomonas spp.
JCM Accepts, published online ahead of print on 12 September 2012 J. Clin. Microbiol. doi:10.1128/jcm.01597-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Rapid detection
More informationPositive for carbapenemase production by a phenotypic method
17-ID-04 Committee: Infectious Disease Title: Public Health Reporting and National Notification of Carbapenemase Producing Carbapenem- Resistant Enterobacteriaceae (CP-CRE) for E. coli, Klebsiella spp.
More information